PriceTargets.com logo

Daré Bioscience - DARE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.33
  • Forecasted Upside: 658.81%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.23 As of 02/6/2023 01:00 AM ET
▼ -0.02 (-1.60%)

This chart shows the closing price for DARE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Daré Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DARE

Analyst Price Target is $9.33
▲ +658.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Daré Bioscience in the last 3 months. The average price target is $9.33, with a high forecast of $17.00 and a low forecast of $4.00. The average price target represents a 658.81% upside from the last price of $1.23.

This chart shows the closing price for DARE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Daré Bioscience. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2023Roth CapitalInitiated CoverageBuyLow
12/13/2022HC WainwrightBoost TargetBuy$6.00 ➝ $7.00Low
11/30/2022JonestradingInitiated CoverageBuyLow
10/18/2022HC WainwrightReiterated RatingBuy$6.00Low
5/13/2022Maxim GroupInitiated CoverageBuy$4.00High
4/1/2022Maxim GroupInitiated CoverageBuy$4.00High
4/1/2022Roth CapitalBoost Target$11.00 ➝ $17.00High
4/1/2022HC WainwrightBoost TargetBuy$5.00 ➝ $6.00High
1/19/2022Brookline Capital ManagementReiterated RatingBuyHigh
12/8/2021HC WainwrightReiterated RatingBuy$5.00High
7/8/2021HC WainwrightReiterated RatingBuyHigh
6/30/2021Roth CapitalBoost TargetBuy$9.00 ➝ $11.00High
3/31/2021HC WainwrightReiterated RatingBuy$5.00Low
2/15/2021AegisReiterated RatingBuyHigh
12/18/2020HC WainwrightInitiated CoverageBuy$5.00High
12/7/2020Roth CapitalBoost TargetBuy$7.00 ➝ $9.00High
9/10/2020Roth CapitalReiterated RatingBuyHigh
7/12/2020Roth CapitalReiterated RatingBuy$4.00High
7/12/2020AegisReiterated RatingBuy ➝ Market Perform$5.00High
7/12/2020Dawson JamesReiterated RatingBuy$3.00High
6/18/2020Maxim GroupReiterated RatingBuy$3.00Low
6/2/2020AegisReiterated RatingBuyHigh
5/15/2020Maxim GroupInitiated CoverageBuy$3.00Low
4/28/2020Brookline Capital ManagementInitiated CoverageBuy$7.50High
4/1/2020Maxim GroupInitiated CoverageBuy$3.00Low
3/31/2020Roth CapitalLower Target$6.00 ➝ $4.00Medium
3/11/2020Maxim GroupReiterated RatingBuy$3.00High
11/12/2019Maxim GroupReiterated RatingBuy$3.00Medium
9/9/2019Maxim GroupInitiated CoverageBuy$3.00High
8/22/2019AegisInitiated CoverageBuyLow
5/16/2019Maxim GroupReiterated RatingBuy$3.00Low
4/4/2019Maxim GroupReiterated RatingBuy$3.00High
12/6/2018Maxim GroupSet TargetBuy$3.00High
11/29/2018Maxim GroupSet TargetBuy$3.00High
11/13/2018Maxim GroupSet TargetBuy$3.00Low
10/30/2018Maxim GroupSet TargetBuy$3.00High
10/15/2018Maxim GroupSet TargetBuy$3.00High
8/17/2018Maxim GroupInitiated CoverageBuy$3.00High
5/16/2018Roth CapitalInitiated CoverageBuy$6.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

0.99 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/9/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Daré Bioscience logo
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $1.23
Low: $1.21
High: $1.25

50 Day Range

MA: $1.03
Low: $0.82
High: $1.36

52 Week Range

Now: $1.23
Low: $0.82
High: $1.88

Volume

182,443 shs

Average Volume

446,523 shs

Market Capitalization

$104.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33

Frequently Asked Questions

What sell-side analysts currently cover shares of Daré Bioscience?

The following sell-side analysts have issued reports on Daré Bioscience in the last year: HC Wainwright, Jonestrading, Maxim Group, and Roth Capital.
View the latest analyst ratings for DARE.

What is the current price target for Daré Bioscience?

3 Wall Street analysts have set twelve-month price targets for Daré Bioscience in the last year. Their average twelve-month price target is $9.33, suggesting a possible upside of 658.8%. Roth Capital has the highest price target set, predicting DARE will reach $17.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $4.00 for Daré Bioscience in the next year.
View the latest price targets for DARE.

What is the current consensus analyst rating for Daré Bioscience?

Daré Bioscience currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DARE will outperform the market and that investors should add to their positions of Daré Bioscience.
View the latest ratings for DARE.

What other companies compete with Daré Bioscience?

Other companies that are similar to Daré Bioscience include Capricor Therapeutics, Opiant Pharmaceuticals, Syros Pharmaceuticals, Vaccitech and Rezolute. Learn More about companies similar to Daré Bioscience.

How do I contact Daré Bioscience's investor relations team?

Daré Bioscience's physical mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company's listed phone number is (858) 926-7655 and its investor relations email address is [email protected] The official website for Daré Bioscience is www.darebioscience.com. Learn More about contacing Daré Bioscience investor relations.